6682.HK
WeRide, Pony AI makes infrastructure

AI applications developer Beijing Fourth Paradigm Intelligent Technology Co. Ltd. (6682.HK) on Monday announced the formation of a joint venture with Beijing Hyperstrong Technology Co. Ltd. The venture, Energy Crystals (Beijing) Technology, will develop AI-driven technology solutions for power trading operations, with Fourth Paradigm holding a 19% stake.

The venture will combine “AI + energy storage” technologies by leveraging Hyperstrong’s expertise in R&D, manufacturing and operational management of energy storage systems. Fourth Paradigm will supply advanced AI-agent infrastructure, including world modeling concepts, machine-learning platforms and energy-solutions frameworks. The venture aims to offer end-to-end AI solutions across electricity-trading mechanisms and energy-asset management ecosystems.

Shares of Fourth Paradigm opened down 1.2% at HK$54.85 on Tuesday. The stock is up 67% from its April low this year.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, clickhere

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…